Pharmacogenomic Effect/ADR for Acenocoumarol (DBSNPE007260)

Identifier
DBSNPE007260
Drug
DB01418 (Acenocoumarol)
Interacting Gene/Enzyme
Cytochrome P450 2C9
Gene Name
CYP2C9
UniProt ID
P11712
Defining Change(s)
1003C>Trs28371685
Allele Name
CYP2C9*11
Genotype(s)
Not Available
Type(s)
Effect Inferred
Groups
Decreased CYP2C9
Description
Poor drug metabolizer, associated with lower dose requirement.
References
  1. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002 Apr 3;287(13):1690-8. [PubMed:11926893]
  2. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA: Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics. 2004 Aug;14(8):527-37. [PubMed:15284535]
  3. King BP, Khan TI, Aithal GP, Kamali F, Daly AK: Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics. 2004 Dec;14(12):813-22. [PubMed:15608560]
  4. Allabi AC, Gala JL, Horsmans Y: CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics. 2005 Nov;15(11):779-86. [PubMed:16220110]
  5. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]